TORNTPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.4
| Stock Code | TORNTPHARM | Market Cap | 1,41,643 Cr. | Current Price | 4,185 ₹ | High / Low | 4,483 ₹ |
| Stock P/E | 63.4 | Book Value | 250 ₹ | Dividend Yield | 0.76 % | ROCE | 27.8 % |
| ROE | 26.2 % | Face Value | 5.00 ₹ | DMA 50 | 4,162 ₹ | DMA 200 | 3,871 ₹ |
| Chg in FII Hold | 0.05 % | Chg in DII Hold | -0.09 % | PAT Qtr | 584 Cr. | PAT Prev Qtr | 606 Cr. |
| RSI | 50.8 | MACD | -4.12 | Volume | 2,99,928 | Avg Vol 1Wk | 3,06,517 |
| Low price | 3,101 ₹ | High price | 4,483 ₹ | PEG Ratio | 2.61 | Debt to equity | 0.25 |
| 52w Index | 78.4 % | Qtr Profit Var | 20.4 % | EPS | 65.0 ₹ | Industry PE | 30.1 |
📈 Optimal Buy Price: 4,160 – 4,180 ₹ (near 50 DMA support)
💰 Profit Exit Levels: 4,220 ₹ (first resistance), 4,260 – 4,280 ₹ (momentum breakout)
⚠️ Stop-Loss: 4,130 ₹ (below support zone)
⏳ Intraday Exit Guidance: If already holding, consider booking profits near 4,220–4,260 ₹ if RSI weakens or volume declines. Exit immediately if price slips under 4,160 ₹ with negative momentum.
Positive
- Strong ROCE at 27.8% and ROE at 26.2% reflect excellent efficiency.
- EPS of 65.0 ₹ supports earnings visibility.
- Price above 200 DMA (3,871 ₹), confirming long-term strength.
- Institutional support: FII holdings increased (+0.05%).
- Quarterly profit variation at 20.4% shows growth stability.
Limitation
- High P/E of 63.4 vs industry PE of 30.1, indicating steep valuation premium.
- MACD negative (-4.12), suggesting weak short-term momentum.
- RSI at 50.8 is neutral, limiting strong signals.
- Volume (2.99 Lakh) slightly below weekly average (3.06 Lakh), showing reduced participation.
Company Negative News
- PAT declined sequentially (584 Cr. vs 606 Cr.), showing mild earnings pressure.
- DII holdings decreased (-0.09%), reflecting weaker domestic institutional support.
Company Positive News
- EPS remains strong despite sequential profit decline.
- FII holdings increased, showing foreign investor confidence.
Industry
- Industry PE at 30.1 indicates sector is moderately valued compared to TORNTPHARM’s premium.
- Pharma sector outlook remains stable with defensive demand characteristics.
Conclusion
⚖️ TORNTPHARM shows solid fundamentals and long-term strength but weak short-term momentum. Suitable for cautious intraday trades targeting 4,220–4,280 ₹ with strict stop-loss at 4,130 ₹. Momentum indicators suggest limited upside unless volume improves.
Would you like me to also prepare a swing trade overlay with broader entry/exit zones and peer benchmarking against Sun Pharma, Dr. Reddy’s, and Cipla for a comparative sector view?